Active Biotech's partner Teva presents data on laquinimod for the treatment of multiple sclerosis at 31st ECTRIMS Congress
October 06 2015 - 8:11AM
Active Biotech (NASDAQ:ACTI) today announces that the collaboration
partner Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
will present data on laquinimod, an investigational therapy being
evaluated in relapsing and progressive forms of MS, at the 31st
European Committee for Treatment and Research in Multiple Sclerosis
(ECTRIMS) Congress in Barcelona, October 7-10, 2015.
For further information, please see www.tevapharm.com.
About Laquinimod
Laquinimod is a once-daily oral, investigational, CNS-active
immunomodulator with a novel mechanism of action being developed
for the treatment of relapsing-remitting MS (RRMS), progressive MS
and Huntington's disease. The global, Phase III, clinical
development program evaluating laquinimod in MS includes two
completed pivotal studies, ALLEGRO and BRAVO (both 0.6mg/day). A
third Phase III trial, CONCERTO, is currently ongoing and
evaluating two doses of laquinimod (0.6mg and 1.2mg/day) in 2,199
patients for up to 24 months. The primary outcome measure is time
to three-month confirmed-disability progression as measured by the
Expanded Disability Status Scale (EDSS).
For further information, please contact: Tomas
Leanderson, President & CEO Tel +46 46 19 20 95 Email:
tomas.leanderson@activebiotech.com
Hans Kolam, CFO Tel +46 46 19 20 44 Email:
hans.kolam@activebiotech.com
Active Biotech AB (publ)
(Nasdaq Stockholm:ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in pivotal phase III development for the treatment
of relapsing remitting multiple sclerosis. Also, laquinimod is in
phase II development for the treatment of primary progressive
multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are ongoing for the projects ISI, ANYARA and
paquinimod. Please visit www.activebiotech.com for more
information.
Active Biotech AB (Corp. Reg. No.
556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained
in this press release in accordance with the Swedish Securities
Market Act and/or the Financial Instruments Trading Act . This
information was provided to the media for publication at 2:00 p .m.
CEST on Oct 6, 2015.
Active Biotech's partner Teva presents data on laquinimod
http://hugin.info/1002/R/1956964/712899.pdf
HUG#1956964
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024